Farhad Ravandi, MD, on AML: Highlights of Ongoing Research
SOHO 2025Farhad Ravandi, MD, provides an overview of acute myeloid leukemia (AML) research highlighted in a session at SOHO, including data on menin inhibitors in NPM1-mutated disease; FLT3 inhibitors in FLT3-mutated disease; IDH inhibitors in IDH1-mutated disease; the role of measurable residual disease; what’s on the horizon for immunotherapy; risk stratification; and a discussion of the use of lower-intensity regimens.